Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Apr;89(4):429-33.
doi: 10.1016/j.mayocp.2014.02.009.

Melanoma resistance: a bright future for academicians and a challenge for patient advocates

Andrzej T Slominski  1 , J Andrew Carlson  2
Affiliations
Editorial

Melanoma resistance: a bright future for academicians and a challenge for patient advocates

Andrzej T Slominski et al. Mayo Clin Proc. 2014 Apr.
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Current approaches to treating metastatic melanoma resemble “Sisyphus work” from Greek mythology. Similar to Sisyphus, it will be problematic to reach the pinnacle where targeted cure is achieved because clonal heterogeneity will overcome the drug effects in most patients with metastatic melanoma. BRAF = proto-oncogene B-Raf; MEK1/2 = mitogen-activated protein kinase kinase 1 or 2; N-RAS = neuroblastoma RAS viral oncogene homolog; PDGFRB = beta-type platelet-derived growth factor; PI3K = phosphatidylinositide 3-kinase; PTEN = phosphatase and tensin homolog.
See this image and copyright information in PMC

Comment on

References

    1. Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014 In press. - PMC - PubMed
    1. Enninga EAL, Holtan SJ, Creedon DJ, et al. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc. 2014 In press. - PMC - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. - PubMed
    1. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365. - PubMed
    1. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 2013;14(8):733–740. - PubMed

Substances